Published in Biochim Biophys Acta on March 16, 1995
Dermatophyte lipids-Composition and regulation of phospholipids. Indian J Clin Biochem (2000) 0.75
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol (2001) 2.69
Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med (2011) 1.93
Detection of hepatitis E virus infections among domestic swine in the Kathmandu Valley of Nepal. Am J Trop Med Hyg (1995) 1.67
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother (2003) 1.49
Cancer control in India- A sorry state. Indian J Cancer (2009) 1.49
Comparison of acute rest myocardial perfusion imaging and serum markers of myocardial injury in patients with chest pain syndromes. J Nucl Cardiol (2000) 1.40
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs (1990) 1.40
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) (2005) 1.25
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) (2003) 1.18
Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J (2000) 1.15
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents (2005) 1.14
In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett (2005) 1.13
Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother (2005) 1.11
Phospholipids of Clostridium butyricum. V. Effects of growth temperature on fatty acid, alk-1-enyl ether group, and phospholipid composition. J Lipid Res (1974) 1.09
Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett (2006) 1.09
Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells. Clin Exp Immunol (2009) 1.08
Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm (2005) 1.04
Longitudinal extensive transverse myelitis due to tuberculosis: a report of four cases. J Postgrad Med (2014) 1.03
Signaling through protein kinases and transcriptional regulators in Candida albicans. Crit Rev Microbiol (2003) 1.02
Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents (2006) 1.02
Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother (2001) 1.01
Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother (2001) 1.01
Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc Soc Exp Biol Med (1997) 0.99
Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int J Pharm (2002) 0.99
Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother (2004) 0.99
Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents (2001) 0.97
A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. Oncogene (2008) 0.97
Further studies on the lipids of corynebacteria. The mannolipids of Corynebacterium aquaticum. Biochem J (1972) 0.96
Rho/ROCK pathway as a target of tumor therapy. J Neurosci Res (2006) 0.96
Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol (2007) 0.95
Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents (2004) 0.94
A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect (2006) 0.94
Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother (1997) 0.94
Effects of growth temperature and supplementation with exogenous fatty acids on some physical properties of Clostridium butyricum phospholipids. Biochim Biophys Acta (1977) 0.94
Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis (2004) 0.93
Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) (2005) 0.92
On the mannophosphoinositides of Mycobacterium 607. Experientia (1968) 0.92
Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 0.92
Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother (2006) 0.92
Biochemical interaction of human neutrophil peptide-1 with Mycobacterium tuberculosis H37Ra. Arch Microbiol (1999) 0.92
Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother (2003) 0.91
Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. Int J Antimicrob Agents (2007) 0.91
Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother (2004) 0.91
Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model. Protein Expr Purif (2006) 0.90
Quiescent-inflow single-shot magnetic resonance angiography using a highly undersampled radial k-space trajectory. Magn Reson Med (2013) 0.90
Comparative evaluation of the diagnostic significance of circulating immune complexes and antibodies to phosphatidylinositomannosides in pulmonary tuberculosis by enzyme-linked immunosorbent assay. Med Microbiol Immunol (1989) 0.90
Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci (2008) 0.90
Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect Immun (2005) 0.90
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother (2004) 0.90
Attenuation of ischemia/reperfusion induced MAP kinases by N-acetyl cysteine, sodium nitroprusside and phosphoramidon. Mol Cell Biochem (2002) 0.90
TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappaB pathway. Oncogene (2009) 0.90
Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins. Eur Respir J (2006) 0.89
DNA vaccines: future strategies and relevance to intracellular pathogens. Immunol Cell Biol (2001) 0.88
Immunoprophylactic properties of 71-kDa cell wall-associated protein antigen of Mycobacterium tuberculosis H37Ra. Med Microbiol Immunol (1997) 0.88
Profile of Circulatory Metabolites in a Relapsing-remitting Animal Model of Multiple Sclerosis using Global Metabolomics. J Clin Cell Immunol (2013) 0.88
Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine (2005) 0.88
Effect of acute administration of dichlorodiphenyl trichloroethane on certain enzymes of Rhesus monkey. Indian J Med Res (1978) 0.88
Cell wall and membrane changes associated with ethambutol resistance in Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother (1990) 0.88
Immunogenicity of ribonucleic acid-protein fraction of Mycobacterium tuberculosis encapsulated in liposomes. J Med Microbiol (1989) 0.87
Polymer based drug delivery systems for mycobacterial infections. Curr Drug Deliv (2004) 0.87
Immunodominance of low molecular weight secretory polypeptides of Mycobacterium tuberculosis to induce cytotoxic T-lymphocyte response. Vaccine (2005) 0.87
Distribution of tannic acid degrading microorganisms in the soil and comparative study of tannase from two fungal strains. Acta Microbiol Pol (2001) 0.87
Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. Clin Immunol (2007) 0.86
Liposomes and PLG microparticles as sustained release antitubercular drug carriers--an in vitro-in vivo study. Int J Antimicrob Agents (2001) 0.86
Liposomes as a carrier for mannophosphoinositide antigens of mycobacteria. Indian J Biochem Biophys (1993) 0.86
Replacement of acyl and alk-1-enyl groups in Clostridium butyricum phospholipids by exogenous fatty acids. Biochemistry (1975) 0.86
Lipid metabolism in fungi. Crit Rev Microbiol (1984) 0.86
Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J Infect (2006) 0.85
Short- and medium-term outcome differences in women and men after primary percutaneous transluminal mechanical revascularization for acute myocardial infarction. Am J Cardiol (2000) 0.85
Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta (1997) 0.85
Suture closure of the femoral arteriotomy following invasive cardiac procedures: a detailed analysis of efficacy, complications, and the impact of early ambulation in 1,200 consecutive, unselected cases. Catheter Cardiovasc Interv (2001) 0.84
Alginate-based sustained release drug delivery systems for tuberculosis. Expert Opin Drug Deliv (2008) 0.84
Effect of growth temperature on the lipid composition of Mycobacterium smegmatis ATCC 607. J Gen Microbiol (1979) 0.83
Grain size effect on the magnetic cluster-glass properties of La0.88Sr0.12CoO3. J Phys Condens Matter (2010) 0.83
Human immune recognition-based multicomponent subunit vaccines against tuberculosis. Eur Respir J (2005) 0.83
Lipid composition and virulence of Mycobacterium tuberculosis H37Rv. Aust J Exp Biol Med Sci (1982) 0.83
Alterations in macromolecular composition and cell wall integrity by ciprofloxacin in Mycobacterium smegmatis. Lett Appl Microbiol (1999) 0.83
Antigenicity of phosphatidyl inositomannosides of Mycobacterium tuberculosis. Immunochemistry (1971) 0.83
A Griffiths-like phase in antiferromagnetic R0.5Eu0.5MnO3 (R = Pr, Nd, Sm). J Phys Condens Matter (2013) 0.83
Pyrazine functionalized Ag(I) and Au(I)-NHC complexes are potential antibacterial agents. Curr Med Chem (2012) 0.82
Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother (2001) 0.82
Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents (2004) 0.82
Decrease in serum matrix metalloproteinase-9 and matrix metalloproteinase-3 levels in Zucker fa/fa obese rats after treatment with swertiamarin. Exp Clin Cardiol (2012) 0.82
Role of cyclic adenosine monophosphate in phospholipid synthesis in Mycobacterium smegmatis ATCC 607. Lipids (1995) 0.81
Central venous catheter disruption and embolization: percutaneous retrieval. A case report. Eur Rev Med Pharmacol Sci (2001) 0.81
Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. FEMS Immunol Med Microbiol (1994) 0.81
Prostaglandins and vasoactive amines in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke (1989) 0.81
External pancreatic secretion after bombesin infusion in man. Gut (1975) 0.81
Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles. FEMS Immunol Med Microbiol (1998) 0.81
Enflurane, halothane, and isoflurane potency in horses. Am J Vet Res (1977) 0.81
Ca2+/calmodulin dependent protein kinase from Mycobacterium smegmatis ATCC 607. Mol Cell Biochem (1998) 0.81
Acid phosphatase activity of promastigotes of Leishmania donovani: a marker of virulence. FEMS Microbiol Lett (1992) 0.80
Nonlinearity exponent of ac conductivity in disordered systems. J Phys Condens Matter (2012) 0.80
Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria. Med Microbiol Immunol (1988) 0.80
Dominant dipolar interaction and glassy magnetic behaviour in polymer-coated magnetite nanoparticles. Nanotechnology (2008) 0.80
Influence of lipid composition on the sensitivity of Candida albicans to antifungal agents. Indian J Biochem Biophys (1989) 0.80
On the ornithinyl ester of phosphatidylglycerol of Mycobacterium 607. J Bacteriol (1970) 0.80
Phospholipid metabolism in Mycobacterium smegmatis ATCC 607 grown at 37 degrees and 27 C degrees C. Arch Microbiol (1981) 0.80